Post
Pfizer’s weight loss drug hits primary endpoint in Phase IIb trial
Pfizer has announced that its Phase IIb trial investigating oral weight loss drug danuglipron has met its primary endpoint. The glucagon-like …
The movement towards trial transparency
Transparency throughout the entire clinical trial industry was a persistent theme at the tenth annual Outsourcing in Clinical Trials DACH …
BlueSkeye AI to begin trial of AI mental health app for perinatal depression
The Medical and Healthcare products Regulatory Agency (MHRA) has greenlit BlueSkeye AI to begin a clinical trial investigating its TrueBlue …
World AIDS Day 2023 highlights community leadership to end the HIV epidemic
1 December commemorates World AIDS Day – a day of awareness and support for those living with HIV/AIDS, as well …
SciNeuro concludes dosing in study of Alzheimer’s therapeutic
SciNeuro Pharmaceuticals has concluded subject dosing in the Phase I clinical study of its oral therapeutic candidate, SNP318, to treat …
Neurogene doses two paediatric patients in trial of Rett Syndrome therapy
Neurogene has dosed the first two female paediatric subjects in Phase I/II trial of its investigational adeno-associated virus (AAV) gene …
Acadia starts Phase III study of PWS therapy
Acadia Pharmaceuticals has commenced the pivotal Phase III study of carbetocin nasal spray (ACP-101) to treat hyperphagia in Prader-Willi syndrome …
Cybin reports positive results from major depressive disorder trial
Cybin has reported positive topline data from the Phase II clinical trial of its deuterated psilocybin analogue, CYB003, to potentially treat major …
Navigating affordable approaches to cell therapy clinical trials
By Luisa Sterkel & Joana Loureiro, Tenthpin Consultants and Dr. Frank Altznauer Chief Industry Advisor at Tenthpin Despite the now evident impact …
Pharma’s engagement with healthcare providers has slipped in recent years
In recent years there has been a downward trend in health care provider (HCP) contact in the pharmaceutical industry with …
Madrigal ramps up preparations for commercial launch of resmetirom in NASH
Following the US Food and Drug Administration's (FDA) acceptance of Madrigal Pharmaceuticals' new drug application and priority review for …
BioVie reports protocol deviations in Phase III Alzheimer’s trial
Clinical-stage biotech BioVie has seen its Phase III Alzheimer’s disease (AD) study impeded by Good Clinical Practice (GCP) violations and …
BiVACOR wins IDE to start first-in-human study for artificial heart
The US Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) to BiVACOR’s total artificial heart (BTAH), …
CTO Europe 2023: Fostering diverse oncology trials remains a challenge
Lacking diversity in clinical trials remains a challenge as 73% of global study participants are white, based on data presented …
AbbVie’s Teliso-V succeeds across key NSCLC endpoints
Biopharma giant AbbVie has announced that pipeline candidate Teliso-V (telisotuzumab-vedotin) demonstrated a clinically meaningful overall response rate (ORR) in a …